Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance)
Christian Niederwieser,
Deedra Nicolet,
Andrew J. Carroll,
Jonathan E. Kolitz,
Bayard L. Powell,
Jessica Kohlschmidt,
Richard M. Stone,
John C. Byrd,
Krzysztof Mrózek,
Clara D. Bloomfield
Affiliations
Christian Niederwieser
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
Deedra Nicolet
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA;Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, Rochester, MN, USA
Andrew J. Carroll
University of Alabama at Birmingham, Birmingham, AL, USA
Jonathan E. Kolitz
Monter Cancer Center, Hofstra North Shore-Long Island Jewish School of Medicine, Lake Success, NY, USA
Bayard L. Powell
Comprehensive Cancer Center, Wake Forest University, Winston-Salem, NC, USA
Jessica Kohlschmidt
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA;Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, Rochester, MN, USA
Richard M. Stone
Dana-Farber Cancer Institute, Boston, MA, USA
John C. Byrd
Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
Krzysztof Mrózek
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
Clara D. Bloomfield
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
Achievement of complete remission is essential for long-term survival of acute myeloid leukemia patients. We evaluated the prognostic significance of cytogenetics at complete remission in 258 adults with de novo acute myeloid leukemia and abnormal pre-treatment karyotypes, treated on Cancer and Leukemia Group B front-line studies, with cytogenetic data at onset of morphological complete remission. Thirty-two patients had abnormal karyotypes at time of initial complete remission. Of these, 28 had at least 1 abnormality identified pre-treatment, and 4 acute myeloid leukemia-related abnormalities not detected pre-treatment. Two hundred and twenty-six patients had normal remission karyotypes. Patients with abnormal remission karyotypes were older (P
